Project Details
Description
A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Advanced or Metastatic Adenocarcinoma of the Pancreas who have failed or are intolerant to First-Line Chemotherapy
| Status | Finished |
|---|---|
| Effective start/end date | 4/15/14 → 4/30/19 |
Funding
- INCYTE CORPORATION
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.